TICKERNERD
Menu
CRBUCRBUHealthcare · Biotechnology

CRBU Stock Forecast: Caribou Biosciences, Inc. Price Predictions for 2026-2027

Last close, 12 Nov 2026
$0.38
−3.53% on the day

The 5 Wall Street analysts covering Caribou Biosciences, Inc. hold a median 12-month price target of $1 — +165.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 11 Nov 2026 — in the lower half.

Market cap
$42.2M
Ticker Nerd rank
43/ 100
Median analyst target
$1.00
Analysts covering
5
Revenue$1.5M−43.8% y/y
Operating income−$25.3M
Net income−$24.3M
Free cash flow−$22.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.4%
1M
−24.1%
YTD
−76.3%
1Y
−83.3%
From 52W high
−84.5%
From 52W low
0.0%
$0.38
$2.43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRBU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Caribou Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Nov 2026
43/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
97
Size
81
Accruals
78
Revisions
74
Issuance
27
Volatility
27
Quality
19
Value
7
Momentum
7

Growth (97): Sales and profits are climbing, and climbing faster than before.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CRBU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRBU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00Jan 26Apr 26Jul 26Oct 26CRBUHigh $13.00Median $1.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
1 Buy4 Hold0 Sell
Low $1.00Median $1.00High $13.00

The green dot is the last close — the median target sits +165.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
8 Oct 2026HC Wainwright & Co.DowngradeNeutral—
7 Oct 2026Brookline CapitalDowngradeHold—
7 Oct 2026Leerink PartnersDowngradeMarket Perform$4.00 → $1.00
7 Oct 2026RBC CapitalDowngradeSector Perform$10 → $1.00
14 Aug 2026B of A SecuritiesMaintainsBuy$6.00 → $5.00
14 Aug 2026B of A SecuritiesMaintainsBuy—
11 May 2026HC Wainwright & Co.MaintainsBuy—
11 May 2026HC Wainwright & Co.MaintainsBuy$9.00 → $11
7 Apr 2026HC Wainwright & Co.ReiteratesBuy—
9 Mar 2026Evercore ISI GroupMaintainsOutperform—
2 Feb 2026Clear StreetInitiatesBuy—
5 Nov 2025HC Wainwright & Co.MaintainsBuy—
3 Nov 2025CitigroupMaintainsBuy—
28 Apr 2025HC Wainwright & Co.MaintainsBuy—
19 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Jan 2025B of A SecuritiesMaintainsBuy—
26 Nov 2024CitigroupMaintainsBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
3 Sept 2024HC Wainwright & Co.ReiteratesBuy—
14 Aug 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CRBU appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CRBU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Nov 2026, Caribou Biosciences, Inc. returned −83.3% against +12.4% for the S&P 500, dividends included.

CRBU vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26CRBUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRBU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Caribou Biosciences, Inc. (CRBU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 80% of US stocks

Price / sales
4.3×

Cheaper than 25% of US stocks

Price / book
0.5×

Cheaper than 81% of US stocks

EV / EBITDA
0.3×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
−26.9%

Higher than 10% of US stocks

Earnings growth (YoY)
−43.8%

Higher than 12% of US stocks

Gross margin
—
Operating margin
−1140.6%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−93.8%

Higher than 14% of US stocks

Return on assets
−42.3%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Caribou Biosciences, Inc. (CRBU) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Caribou Biosciences, Inc. has a market value of $42.2M and an enterprise value of −$26.3M.

  • Revenue in the twelve months to 30 June 2026: $10.0M. The latest quarter shrank 26.9% year on year.

  • Net income over the same four quarters: −$103.4M, a −1030.4% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.08.

  • Free cash flow in the twelve months to 30 June 2026: −$95.8M.

  • Shares outstanding: 106.0M.

  • Trailing P/E: −0.2×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Caribou Biosciences, Inc. employs 97 people — $103K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Nov 2026

Data provided by Twelve Data

Peers

CRBU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRBUCaribou Biosciences, Inc.$42.2M43
HYPDHyperion DeFi, Inc.$41.1M40
TILInstil Bio, Inc.$42.8M40
CNTBConnect Biopharma Holdings Ltd.$43.4M41
TELOTelomir Pharmaceuticals, Inc.$43.8M32
IMAImageneBio, Inc.$43.9M33
KLRSKalaris Therapeutics, Inc.$39.8M31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Caribou Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRBU news & analysis

Caribou Biosciences (CRBU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Zacks Investment Research · 12 Nov 2026positive

Caribou Biosciences (CRBU) formed a hammer chart pattern after recent losses, which the source says indicates potential support. The excerpt also reports that Wall Street analysts have broadly revised earnings estimates higher.

Why it matters — CRBU watchers may note the reported technical support signal and upward earnings-estimate revisions as factors the source associates with possible near-term turnaround potential.

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue Estimates

Zacks Investment Research · 6 Nov 2026positive

Caribou Biosciences reported a third-quarter loss of $0.25 per share, compared with the Zacks consensus estimate of a $0.27 loss. The loss was $0.30 per share in the year-ago quarter.

Why it matters — CRBU watchers may note that the reported quarterly loss was narrower than the consensus estimate and the year-ago loss.

FAQ

Frequently asked questions about CRBU stock

What is the CRBU stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Caribou Biosciences, Inc. have a median 12-month price target of $1, with estimates ranging from $1 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRBU stock a buy right now?

Of the 5 analysts covering Caribou Biosciences, Inc., 1 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Caribou Biosciences, Inc. 43 out of 100 across roughly 4,600 US stocks as at 11 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRBU?

As at 11 Nov 2026, Caribou Biosciences, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (97 of 100).

Will CRBU stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +165.1% from the last close, and Ticker Nerd's factor model ranks Caribou Biosciences, Inc. 43 out of 100 as at 11 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRBU stock forecast for 2030?

No analyst covering Caribou Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRBU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $13 over the next 12 months.

How has CRBU stock performed over the past year?

Caribou Biosciences, Inc. returned -83.3% over the 12 months to 12 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Caribou Biosciences, Inc. do?

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies using its CRISPR-based chRDNA platform.

What is the latest news on CRBU?

The most recent item we track (Zacks Investment Research, 12 Nov 2026): "Caribou Biosciences (CRBU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?". Caribou Biosciences (CRBU) formed a hammer chart pattern after recent losses, which the source says indicates potential support. The excerpt also reports that Wall Street analysts have broadly revised earnings estimates higher.

Company

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies using its CRISPR-based chRDNA platform. The company works on off-the-shelf CAR-T and CAR-NK therapies designed to support precise cell engineering for difficult-to-treat diseases. Its current pipeline centers on hematologic malignancies and autoimmune disorders, with programs that include anti-CD19, anti-BCMA, and anti-CD371 cell therapies in clinical development. Caribou Biosciences also applies its gene-editing technology to advance broader research and therapeutic applications in biotechnology. Headquartered in Berkeley, California, the company operates as a single business segment centered on next-generation cell therapy development.

CEO Dr. Rachel E. Haurwitz Ph.D. · 97 employees · United States · https://cariboubio.com